Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Viral Hepat
Main Authors: Flamm, Steven, Mutimer, David, Asatryan, Armen, Wang, Stanley, Rockstroh, Jürgen, Horsmans, Yves, Kwo, Paul Y., Weiland, Ola, Villa, Erica, Heo, Jeong, Gane, Edward, Ryder, Stephen D., Welzel, Tania M., Ruane, Peter J., Agarwal, Kosh, Ng, Teresa I., Xue, Zhenyi, Lovell, Sandra S., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Trinh, Roger, Mensa, Federico J., Wyles, David L.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379735/
https://ncbi.nlm.nih.gov/pubmed/30421537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13038
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares